Good luck to those who want to shame Celgene
Celgene is getting unwanted attention for the high price of Revlimid, but its pivotal position in multiple myeloma could help the company resist a shame campaign.
M&A comes back with a bang – or two – in medtech
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
